CLVT Clarivate Plc
USTechnologyAs of 2026-07-09 16:00
Why CLVT matters now
Clarivate Plc (CLVT) is a US stock in Technology. The latest InvestLog snapshot shows $2.20 with -0.45% on the session and $1.41B in market capitalization; recent performance reads 1-month -17.74% and YTD -38.92%.
The latest financial table shown here is Q1 2026, with revenue of $585.5M, net income of $-40.2M, and EPS of $-0.06. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield 45.8%.
The latest indexable market news headline is "Clarivate Plc (CLVT) M&A Call Transcript" from Seeking Alpha.
Additional event context on this page matters because analyst consensus is Hold with a median target of $3.60; recent insider activity includes Webster Simon filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.27
P/S
0.53
EV/EBITDA
5.82
DCF Value
$-7.57
FCF Yield
45.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
66.5%
Operating Margin
5.0%
Net Margin
-5.6%
ROE
-2.8%
ROA
-1.3%
ROIC
1.3%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $585.5M | $-40.2M | $-0.06 |
| Q4 2025 | $617.0M | $3.1M | $0.00 |
| FY 2025 | $2.46B | $-201.1M | $-0.30 |
| Q3 2025 | $623.1M | $-28.3M | $-0.04 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$3.60
Target (Median)
$3.60
Target Range
$3.60 - $3.60
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Technology
Industry
Information Technology Services
Country
GB
Exchange
—
Beta
1.37
Clarivate Plc operates as a prominent information services and analytics firm, furnishing structured data and insights. Its core mission is to facilitate the discovery, safeguard the intellectual property, and enable the commercialization of scientific research, innovations, and established brands. The company's portfolio includes the extensive Web of Science suite, a collection of essential tools such as Web of Science, InCites, Journal Citation Reports, EndNote, ScholarOne, Converis, Publons, and Kopernio. These are designed to support organizations throughout the entire research lifecycle, from initial planning and funding to execution and utilization. Within the Life Sciences domain, Clarivate provides specialized products like Cortellis and Newport Integrity. These platforms cater to pharmaceutical and biotechnology companies, empowering their research endeavors, supplying vital market intelligence, and facilitating competitive monitoring during the development and launch phases of novel drugs. Its Derwent product line, comprising Derwent Innovation, Techstreet, and IP Professional Services, is dedicated to intellectual property management. These tools enable customers to evaluate the originality of potential products, establish their freedom to operate within design parameters, secure patent protection, analyze the competitive technological landscape, and ensure adherence to essential industry standards. Complementing these, CompuMark delivers trademark screening, search, and monitoring solutions vital for businesses and legal firms. Meanwhile, MarkMonitor empowers enterprises to establish, manage, optimize, and fortify their digital presence. Clarivate's diverse clientele spans government agencies, academic institutions, life science enterprises, and research and development corporations worldwide, with operations across the Americas, Middle East, Africa, Europe, and Asia Pacific regions. The company, initially known as Clarivate Analytics Plc, rebranded to Clarivate Plc in May 2020. It maintains its headquarters in London, United Kingdom.